Literature DB >> 7622421

Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice.

H Iseki1, N Kajimura, C Ohue, R Tanaka, Y Akiyama, K Yamaguchi.   

Abstract

To identify the so-called toxohormone, which is a tumor-derived factor with activity to induce cancer cachexia syndrome in tumor-bearing animals, 5 human cancer cell lines with this activity were studied for cytokine production. Tumor cell products with activity to inhibit lipoprotein lipase (LPL) were shown to play an important role in the development of the cancer cachexia syndrome. All culture media conditioned by the 5 cell lines possessed LPL-inhibitory activity. However, the activity differed with the cell line. In order to characterize the activity, we examined whether the cultured cells produced cytokines with activity to inhibit LPL. A melanoma cell line, SEKI, and a neuroepithelioma cell line, NAGAI, were found to express a large amount of leukemia inhibitory factor (LIF) mRNA. Furthermore, both of these cell lines were demonstrated to produce a large amount of LIF protein, and plasma levels of LIF were extremely elevated in SEKI- and NAGAI-bearing nude mice, indicating that LIF produced by the tumor cells induced cancer cachexia syndrome in the animals. Thus, LIF fulfills the requirements for a toxohormone, except for suppressive activity on liver catalase. In contrast, the mechanisms responsible for cachexia in the MKN-1-, LX-1- and LS180-bearing mice remain unknown. These findings suggest that various types of bioactive substances produced by cancer cells could be toxohormones.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622421      PMCID: PMC5920868          DOI: 10.1111/j.1349-7006.1995.tb02435.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  25 in total

1.  In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets.

Authors:  S Asano; A Okano; K Ozawa; T Nakahata; T Ishibashi; K Koike; H Kimura; Y Tanioka; A Shibuya; T Hirano
Journal:  Blood       Date:  1990-04-15       Impact factor: 22.113

2.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

3.  Primitive neuroectodermal tumor (neuroepithelioma) of spinal nerve root -- Report of an adult case and establishment of a cell line.

Authors:  S Ishikawa; Y Ohshima; T Suzuki; S Oboshi
Journal:  Acta Pathol Jpn       Date:  1979-03

4.  Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia.

Authors:  M Mori; K Yamaguchi; K Abe
Journal:  Biochem Biophys Res Commun       Date:  1989-05-15       Impact factor: 3.575

5.  Human colonic adenocarcinoma cells. I. Establishment and description of a new line.

Authors:  B H Tom; L P Rutzky; M M Jakstys; R Oyasu; C I Kaye; B D Kahan
Journal:  In Vitro       Date:  1976-03

6.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

7.  Structure of the human immune interferon gene.

Authors:  P W Gray; D V Goeddel
Journal:  Nature       Date:  1982-08-26       Impact factor: 49.962

8.  Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy.

Authors:  B C Giovanella; J S Stehlin; L J Williams; S S Lee; R C Shepard
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

9.  Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells.

Authors:  J S Patton; H M Shepard; H Wilking; G Lewis; B B Aggarwal; T E Eessalu; L A Gavin; C Grunfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Studies of endotoxin-induced decrease in lipoprotein lipase activity.

Authors:  M Kawakami; A Cerami
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  5 in total

Review 1.  The Molecular Basis and Therapeutic Potential of Leukemia Inhibitory Factor in Cancer Cachexia.

Authors:  Ruijiang Zeng; Chang Tong; Xiangyang Xiong
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

2.  Expression of leukemia inhibitory factor in craniopharyngioma.

Authors:  A Tran; K Kovacs; L Stefaneanu; G Kontogeorgos; B W Scheithauer; S Melmed
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

3.  Metabolic and morphologic characteristics of adipose tissue associated with the growth of malignant tumors.

Authors:  O Ishiko; S Nishimura; T Yasui; T Sumi; K Hirai; K Honda; S Ogita
Journal:  Jpn J Cancer Res       Date:  1999-06

4.  In vivo effect of recombinant human leukemia inhibitory factor in primates.

Authors:  Y Akiyama; N Kajimura; J Matsuzaki; Y Kikuchi; N Imai; M Tanigawa; K Yamaguchi
Journal:  Jpn J Cancer Res       Date:  1997-06

5.  Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.

Authors:  Susan C Kandarian; Rachel L Nosacka; Andrea E Delitto; Andrew R Judge; Sarah M Judge; John D Ganey; Jesse D Moreira; Robert W Jackman
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-09-30       Impact factor: 12.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.